Form 4: Astrana Health Chief Medical Officer Reports Share Transaction for Tax Obligations

Astrana Health's Chief Medical Officer, Dinesh M. Kumar, reported the surrender of 6,831 shares of common stock valued at $25.06 per share to cover tax withholding obligations related to restricted stock vesting, maintaining a beneficial ownership of 218,811 shares.

Summary

• Dinesh M. Kumar, Chief Medical Officer of Astrana Health, Inc. (ASTH), reported a transaction on July 1, 2025.
• The transaction involved the disposition of 6,831 shares of common stock at a price of $25.06 per share.
• This share surrender was specifically to offset tax withholding obligations associated with the vesting of certain restricted stock.
• Following this transaction, Dinesh M. Kumar beneficially owns 218,811 shares of Astrana Health common stock.
• The beneficial ownership includes various restricted stock and restricted stock units with different vesting schedules and conditions.
• Specifically, 56,754 restricted shares will vest in two equal annual installments starting January 23, 2026.
• An additional 13,464 restricted shares are set to vest on January 1, 2026.
• Grants of 8,158 shares and 3,264 shares of restricted stock will vest upon the achievement of certain performance goals.
• 67,238 restricted stock units (RSUs) will vest subject to the achievement of specific performance goals.
• 26,701 RSUs will vest in eight equal semi-annual installments beginning on September 5, 2025.
• The total beneficial ownership also includes 629 shares acquired under Astrana Health's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction related to tax obligations from equity vesting. It is neutral in sentiment, reflecting standard corporate compensation practices without indicating positive or negative operational or financial performance.

Positives

• The Chief Medical Officer maintains a substantial beneficial ownership of 218,811 shares, indicating continued alignment with shareholder interests.
• The transaction is a routine event related to tax obligations from equity vesting, not a discretionary sale.

Negatives

• A reduction of 6,831 shares in direct ownership occurred due to tax withholding, though this is a common practice for equity compensation.

Future Outlook

Future beneficial ownership includes significant tranches of restricted stock and restricted stock units that are scheduled to vest on specific dates or upon the achievement of certain performance goals, indicating a long-term incentive structure for the Chief Medical Officer.

Industry Context

This Form 4 filing reflects a routine insider transaction common across publicly traded companies, particularly in the healthcare sector, where executive compensation often includes equity awards that vest over time. The surrender of shares for tax purposes is a standard mechanism for managing the tax implications of such vesting events.

Stakeholder Impact

• Shareholders: The transaction is a routine tax-related disposition and does not significantly alter the overall share structure or management's commitment, as the Chief Medical Officer retains substantial beneficial ownership.
• Employees: The details of equity vesting and the Employee Stock Purchase Plan indicate standard compensation practices that could be relevant to other employees with similar equity awards.

Next Steps

• Continued vesting of 56,754 restricted shares in two equal annual installments beginning January 23, 2026.
• Vesting of 13,464 restricted shares on January 1, 2026.
• Vesting of 8,158 and 3,264 restricted shares subject to achievement of performance goals.
• Vesting of 67,238 restricted stock units subject to achievement of performance goals.
• Continued vesting of 26,701 restricted stock units in eight equal semi-annual installments beginning September 5, 2025.

Key Dates

Recommendation

Keywords

Astrana Health, ASTH, SEC Form 4, Insider Transaction, Stock Vesting, Restricted Stock, Restricted Stock Units, Tax Withholding, Employee Stock Purchase Plan, Chief Medical Officer, Dinesh M. Kumar